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Abstract
The reduced folate carrier (RFC1) is a major route for the transport of folates in mammalian cells. The localization of
RFC1 in murine tissues was evaluated by immunohistochemical analysis using a polyclonal antibody to the C-terminus of the
carrier. There was expression of RFC1 in the brush-border membrane of the jejunum, ileum, duodenum and colon. RFC1
was localized to the basolateral membrane of the renal tubular epithelium. Carrier was detected on the plasma membrane of
hepatocytes but not in bile duct epithelial cells. In the choroid plexus RFC1 was highly expressed at the apical surface. It was
also expressed in axons and dendrites and on the apical membrane of cells lining the spinal canal. In spleen, RFC1 was
detected only in the cells of the red pulp. These data provide insights into the role that RFC1 plays in folate delivery in a
variety of tissues. In particular, the localization of carrier may elucidate the role of RFC1 in the vectorial transport of folates
across epithelia. The data also indicate that in kidney tubules and choroid plexus the sites of RFC1 expression are different
from what has been reported previously for the folate receptor; and while RFC1 is expressed in small intestine, folate
receptor is not. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Folates are key one-carbon donors critical to the
synthesis of purines, thymidylate and methionine [1].
Folate-dependent enzymes have long been exploited
as chemotherapeutic targets for antimetabolites ^
classically methotrexate (MTX), a potent inhibitor
of dihydrofolate reductase [2]. More recently antifo-
lates have been developed that are direct inhibitors of
folate-dependent enzymes required for purine and
thymidylate biosynthesis [3^5]. The membrane trans-
port of folates and antifolates has been an area of
considerable interest because of the role that these
processes play in intestinal folate absorption, the de-
livery of physiological folates to peripheral tissues
and as determinants of tumor cell cytotoxicity, selec-
tivity and resistance to antifolates [6,7].
Folates are transported into mammalian cells via
several distinct systems. Folate receptors mediate
transport by an endocytotic, energy-requiring process
and several folate receptor isoforms have been cloned
from human and murine tissues [6,8^11]. The re-
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duced folate carrier (RFC1), a classical facilitative
mechanism, delivers folates to hematopoietic and a
variety of other tissues and plays a key role in me-
diating transport of antifolates [2,7,12]. This system
is capable of producing uphill transport of folates
into cells via an anion exchange mechanism with
organic phosphates that are concentrated within cells
[13]. There are, in addition, transport routes for fo-
lates that operate optimally at low pH [14,15] along
with families of organic anion transporters some of
which have a⁄nities for folates in the range of those
observed with RFC1 [16^19]. Folates and antifolates
are also substrates for energy-dependent exporters
[20,21]. Cells that express multidrug resistance pro-
teins (MRPs) are resistant to MTX as well as other
drugs and in some cases export of MTX has been
demonstrated [22^25].
The distribution of folate receptors in the tissues
of di¡erent species has been demonstrated by immu-
nohistochemistry [26^31]. Although the functional
properties of RFC1 have been studied in detail in
many di¡erent cell systems, little is known about
the tissue distribution of RFC1 protein and its dis-
position within cells beyond its apical localization in
retinal pigment epithelium [29]. This report is the
¢rst description of RFC1 protein localization in
mouse tissues.
2. Materials and methods
2.1. Mouse
C57BL/6 adult mice (18^22 g) were fed a normal
diet and killed by cervical dislocation. The intestines
were immediately removed and £ushed repeatedly
with ice-cold 0.01 M PBS bu¡er. Jejunum, duode-
num, ileum and colon were cut into small fragments,
laid onto foil, and quickly placed into a deiced solu-
tion. Liver, spleen and kidney were also cut into
blocks and treated the same way. The skull was
opened and the whole brain, with the very upper
part of spinal cord, was removed gently and placed
in deiced solution. All the samples were then stored
at 380‡C before processing for continuous cryosec-
tioning at 5-Wm thickness. The brain was similarly
cryosectioned from cerebrum to medulla oblongata
and into the proximal spinal canal.
2.2. Antibody
This laboratory has developed a polyclonal anti-
body, AE390, targeted to the distal C-terminus of
mouse RFC1 (Met499 through Ala512). The peptide
was synthesized by the Proteomics Facility at the
Albert Einstein College of Medicine Comprehensive
Cancer Center and coupled to keyhole limpet hemo-
cyanin (Pierce). Antisera was produced in rabbits by
Covance (Denver, PA) and antibody was puri¢ed on
an a⁄nity column to which the corresponding pep-
tide antigen was covalently linked to SulfoLink Cou-
pling gel (Pierce) [32].
2.3. Western blot
A murine L1210 leukemia cell line (R16) with a
high level of RFC1 expression [33] was used to assess
the RFC1 antibody. Total lysate from 2U107 cells
containing proteinase inhibitor (Sigma) was soni-
cated on ice for 20 s. The protein concentration
was determined with the BCA Protein Assay kit
(Pierce); 2.5 Wg of protein was then utilized for so-
dium dodecyl sulfate^polyacrylamide gel electropho-
resis (SDS^PAGE). The loading bu¡er consisted of
62.5 mM Tris^HCl (pH 6.8) containing 10% glycerol,
2% SDS, 5% 2-mercaptoethanol and 0.00125% bro-
mophenol blue without dithiothreitol. Protein was
dissolved in the loading bu¡er at room temperature
[32]. The samples were electrophoresed on 10% SDS^
PAGE gels and transferred to PVDF ¢lters. The
blots were probed with a⁄nity-puri¢ed rabbit anti-
mouse RFC1 antibody (AE390) or preimmune se-
rum, obtained from rabbits before immunization,
followed by peroxidase-conjugated goat anti-rabbit
IgG (Promega, Madison, WI). The blots were en-
hanced by chemiluminescence detection according
to the manufacturer’s instructions (Amersham).
2.4. Immunohistochemical staining
Cryosections were dried at room temperature,
¢xed in cold acetone for 20 min, then washed in
phosphate-bu¡ered saline (PBS, pH 7.4) for 15 min.
Endogenous peroxidase activity was quenched by im-
mersion of slides into 3% H2O2 for 15 min. After
rinsing with PBS three times, tissue was incubated
with 5% normal goat serum at room temperature
BBAMEM 78109 13-6-01 Cyaan Magenta Geel Zwart
Y. Wang et al. / Biochimica et Biophysica Acta 1513 (2001) 49^5450
for 30 min before loading primary antibody (AE390)
overnight at 4‡C. Control slides were treated in the
same way with preimmune serum. Each slide was
then washed three times with PBS bu¡er, incubated
with biotin-labeled goat anti-rabbit IgG, then
washed thrice and incubated with an avidin^biotin
complex. The reaction was enhanced with the TSA
Signal Increasing System according to the kit instruc-
tions (NEN Life Science). The reaction was then
developed with 3,3P-diaminobenzidine tetrahydro-
chloride. Slides were counterstained with Mayer’s
hematoxylin and mounted in cytoseal1 280.
3. Results
3.1. Western blot
To con¢rm the speci¢city of the polyclonal anti-
body, total lysate from R16 cells was immunoblotted
with the AE390 antibody. A single strong band was
detected at 58 kDa which represents murine RFC1
[32]. No band was detected with the preimmune se-
rum, indicating that the AE390 antibody was speci¢c
for RFC1 (Fig. 1).
3.2. RFC1 distribution and tissue localization
3.2.1. Intestine
The AE390 antibody produced a strong immuno-
positive signal localized to the brush-border mem-
brane of jejunum (Fig. 2A). The brush-border mem-
branes of ileum, duodenum and colon were also pos-
itive for the AE390 antibody (not shown). No
staining was detected in the sections incubated with
the preimmune serum. No signal was detected in the
lamina propria, muscularis mucosa, submucosa,
muscularis externa, or smooth muscle cells of the
large and small intestine.
3.2.2. Kidney
RFC1 was detected in the basolateral membrane
of cortical (Fig. 2B) and medullary (not shown) renal
tubular epithelial cells. The cellular distribution was
most apparent from the oil-immersion high-power
view (Fig. 2C). No signal was detected in the glomer-
uli.
3.2.3. Liver
RFC1 was evenly distribution on hepatocyte mem-
branes within the liver lobule (Fig. 2D). No RFC1
signal was found in the bile duct epithelial or stromal
cells. There was no reaction in the presence of the
preimmune serum. RFC1 was not detected within the
hepatocytes.
3.2.4. Brain
The choroid plexus is a polarized tissue with mi-
crovilli facing the cerebrospinal £uid and the basal
membrane in proximity to the capillary bed. RFC1
was detected only on the brush-border membrane.
Carrier was also detected in axons and dendrites
(Fig. 2E inset). RFC1 was noted at the brush-border
membrane of cells lining the spinal canal (not
shown). No positive signal was detected with the
preimmune serum.
3.2.5. Spleen
RFC1 was detected on the membrane of cells in
the red pulp but not on the cells in the white pulp of
the spleen (Fig. 2F). No signal was detected in spleen
incubated with the preimmune serum.
4. Discussion
Dietary folates are delivered into the intestinal lu-
men as polyglutamates where they are hydrolyzed to
monoglutamates then transported into enterocytes
within the small intestinal villus. This is followed
by transport across the basolateral membrane into
the submucosa, di¡usion into the portal capillary
network, then transport to, and storage in, the liver
Fig. 1. Speci¢city of the AE390 antibody against the mouse
RFC1 C-terminus by Western blot analysis. RFC1 from total
R16 cell lysate was immunoblotted by AE390 (A) or the preim-
mune rabbit serum (B) (see Section 2.3).
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[34]. Folates are then released from liver and deliv-
ered via the systemic circulation to peripheral tissues.
Folates delivered to the kidney are largely ¢ltered at
the glomerulus then reabsorbed by the renal tubular
epithelial cells. Within the central nervous system
folates are transported across the choroid plexus
[35] and a gradient is maintained between blood
and cerebrospinal £uid [36]. The goal of the present
study was to determine the localization of RFC1 in
several tissues that have a high requirement for fo-
lates, serve as storage sites, or are important to folate
homeostasis. Of particular interest was the localiza-
tion of RFC1 within cells as a basis for better under-
standing the role of this transporter in the processes
that govern the vectorial £ows of folates across epi-
thelial tissues.
These studies demonstrate that RFC1 is expressed
in many di¡erent tissues but the site of expression
within cells varies from tissue to tissue. RFC1 is lo-
calized to the brush-border membrane of small and
large intestinal epithelial cells with the most intense
signal in the jejunum. Since RFC1 generates trans-
membrane gradients for folates across cell mem-
branes [13,33,37] it is possible that transport across
the apical brush-border membrane generates a small
intracellular folate electrochemical potential with
Fig. 2. Immunohistochemical analysis of mouse tissues exposed to RFC1 C-terminus antibody AE390. (A) Jejunum (250U) ; RFC1 lo-
calized to the brush-border membrane. (B) Renal cortex (250U) ; RFC1 localized to the tubules, not glomeruli. (C) Renal cortex
(1000U) with RFC1 located at the basolateral membrane of renal tubule cells. (D) liver (400U) ; RFC1 signal is localized to the hepa-
tocyte plasma membrane. (E) Choroid plexus (250U) ; RFC1 signal is on the brush-border membrane of choroid plexus epithelial
cells ; inset shows an RFC1-positive axon and dendrite (400U). (F) Spleen (100U) ; RFC1-positive cells are located in red pulp (RP)
not in the white pulp (WP).
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subsequent downhill £ow of folates across the baso-
lateral membrane into the submucosal capillary net-
work. In addition, MRP exporters that transport fo-
lates [38,39], (MRP2 is expressed in the basolateral
membrane of murine intestinal epithelial cells [40]),
could produce the major driving force for folate ab-
sorption by pumping folates out of cells into the
submucosal space. Folate receptors are not expressed
in the small intestine and hence play no role in the
absorptive process [26,28,41].
The pattern of RFC1 distribution in the kidney
was di¡erent from that of the gut. Carrier was ex-
pressed in the basolateral membrane. Murine folate
receptors, on the other hand, are expressed at the
brush-border membrane of renal tubular epithelial
cells [26,31]. This suggests that the receptors play a
major role in the extraction of folates from the glo-
merular ¢ltrate and their delivery into renal tubular
epithelial cells by endocytosis and that this is fol-
lowed by RFC1 mediated transport across the baso-
lateral membrane. This is a somewhat surprising se-
quence since folate receptor turnover is quite slow,
indeed, an order of magnitude slower than that of
RFC1 [42], and an unlikely mechanism to e⁄ciently
extract substrates from ¢ltrate as it £ows through the
tubules. Besides these systems there is a family of
organic anion facilitative carriers expressed in the
kidney (OATK1, OATK2), that are localized to the
brush-border membrane [17,18]. These transporters
may also contribute to folate reabsorption in the
kidney.
RFC1 expression was uniformly pronounced in
the hepatocyte plasma membrane within the liver
lobule as observed also for folate receptor [41]. It
was not expressed in bile duct epithelial cells. It is
of interest that transport of folates in isolated hepa-
tocytes manifests properties that are di¡erent from
RFC1-mediated transport in hematopoietic and oth-
er cells [43^45]. This may be due to tissue-speci¢c
factors that modulate RFC1 function as appears to
occur in the intestine where RFC1 is predominantly
a process with a low pH optimum and high a⁄nity
for folic acid whereas in hematopoietic cells trans-
port is optimum at pH 7.4 and the a⁄nity for folic
acid is two orders of magnitude lower [46]. The
canalicular multispeci¢c organic anion transporter
(cMOAT-MRP2) and MRP3 may play important
roles in biliary excretion of folates [25,47].
There was high-level RFC1 expression on the ap-
ical membrane of the bulbous microvilli of the cho-
roid plexus epithelium adjacent to the ventricular
cavity. On the other hand, folate receptor is localized
to the basolateral membrane of the choroid plexus
[27]. RFC1 was also detected in the apical membrane
of the epithelial cells lining the spinal canal and high-
level expression was also found in dendrites and ax-
ons. The latter is of particular interest since high
folate requirement is usually associated with rapidly
proliferating cells. It may be that these one-carbon
donors play other important roles in meeting the
specialized needs of neural cells [48,49].
RFC1 was localized to the red pulp of the spleen,
which consists primarily of venous sinusoids, splenic
cords, and a variety of free cells of hematopoietic
origin. This is consistent with the marked atrophy
of the red pulp of the spleen and other hematopoietic
organs in mice in which RFC1 has been inactivated
by homologous recombination [50]. No RFC1 was
detected in cells of the white pulp of the spleen, sug-
gesting that resting T and B lymphocytes lack carrier
expression. However, unlike resting cells, mitogen-
activated lymphocytes are sensitive to MTX [51,52]
and lymphoblasts express RFC1 and transport the
drug [53,54]. It is of interest that folate receptors
are found in lymph organs and some leukemia cells
suggesting that transport by this route also plays a
role in the delivery of folates to hematopoietic tissues
[55^57].
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